AMGN

CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder

02/06 02:52 pm

Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management

02/06 06:00 am

Amgen Hits 52-Week Highs: Buy Signal?

02/05 04:43 am

Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth

02/04 01:54 pm

CytomX Therapeutics to Present at Upcoming February Conferences

02/04 09:00 am

Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica

02/03 02:56 am

This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend

02/02 07:33 am

Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis

01/31 11:28 am

Kyowa Kirin akan Mengambil Alih Semula Kawalan ke atas Rocatinlimab Development and Commercialization Program, Sekali Gus Menunjukkan Komitmen Kukuh bagi Menangani Keperluan Perubatan Tinggi yang Belum Dipenuhi dalam Dermatitis Atopik

01/31 11:28 am

Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique

01/31 11:28 am

協和キリン (Kyowa Kirin)、ロカチンリマブ (Rocatinlimab) の開発・商業化プログラムの管理権を再取得、アトピー性皮膚炎における高いアンメット・メディカル・ニーズへの強いコミットメントを示す

01/31 11:28 am

Kyowa Kirin תשיב לעצמה שליטה על תוכנית הפיתוח והמסחור של רוקטינלימאב, תוך הפגנת מחויבות חזקה לטיפול בצורך רפואי גבוה שלא הגיב בדלקת עור אטופית

01/31 11:28 am

Kyowa Kirin 将重新掌控罗卡替尼单抗的研发及商业化项目，展现其致力于满足特应性皮炎医疗需求巨大缺口的坚定决心

01/31 11:28 am

Kyowa Kirin Recupera Controle do Programa de Desenvolvimento e Comercialização do Rocatinlimab, Demonstrando Forte Compromisso para Abordar a Alta Necessidade Médica Não Atendida na Dermatite Atópica

01/31 11:28 am

Kyowa Kirin recupera el control del programa de desarrollo y comercialización de rocatinlimab, demostrando un firme compromiso para abordar la elevada necesidad médica no cubierta en la dermatitis atópica

01/31 11:28 am

Kyowa Kirin 重掌羅卡替尼單抗的研發和商業化項目，展現出致力解決異位性皮膚炎高度未獲滿足醫療需求的堅定承諾

01/31 11:28 am

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

01/30 02:09 pm

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

01/28 09:30 pm

Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR

01/27 11:00 am

Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative

01/21 10:43 am

U.S. Bispecific Antibodies Forecast Report 2025-2033: Market to Grow by Over $260 Billion, Driven by Increased Cancer and Autoimmune Diseases, FDA Approvals, and Strategic Partnerships

01/21 05:52 am

Continuous Bioprocessing Market Set to Surpass Valuation of US$ 2,331.98 Million By 2035 | Astute Analytica

01/16 01:38 pm

Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends

01/16 05:56 am

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

01/14 01:36 pm

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

01/14 04:30 am

The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%

01/09 08:09 am

Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

01/07 02:45 pm

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

01/07 06:00 am

The Best Dividend ETF to Buy: SCHD Pays a High Yield While VIG Focuses on Dividend Growth

12/21 01:18 pm

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

12/16 01:11 pm

Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?

12/16 01:07 pm

Here's How Many Shares of SCHD You'd Need for $1,000 in Yearly Dividends

12/16 08:17 am

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

12/15 11:25 am

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever.

12/14 06:15 am

FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease

12/12 01:43 pm

FDA Approves Amgen's Drug For Rare Muscle Disorder

12/12 12:30 pm

Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer

12/11 08:00 am

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

12/09 05:01 pm

Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - SNS Insider

12/06 10:10 am

3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026

12/04 07:15 am

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

12/01 12:15 am

Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva®

11/25 08:06 pm

Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva®

11/25 08:06 pm

Hospital Care Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 726 Deals by Company A-Z, Therapy Focus and Technology Type

11/19 11:59 am

Metabolic Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 576 Deals by Company A-Z, Therapy Focus and Technology Type

11/19 11:58 am

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday?

11/18 02:15 pm

This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?

11/17 06:25 am

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

11/13 09:00 am

Is the Schwab U.S. Dividend Equity ETF the "Ultimate Retirement Fund" for Investors?

11/13 05:08 am

Why Amgen Stock Was a Nearly 5% Winner Today

11/11 06:31 pm